KYORIN Pharmaceutical Past Earnings Performance

Past criteria checks 1/6

KYORIN Pharmaceutical's earnings have been declining at an average annual rate of -5.4%, while the Pharmaceuticals industry saw earnings growing at 1.2% annually. Revenues have been growing at an average rate of 2.3% per year. KYORIN Pharmaceutical's return on equity is 3.7%, and it has net margins of 4%.

Key information

-5.4%

Earnings growth rate

-5.4%

EPS growth rate

Pharmaceuticals Industry Growth	6.0%
Revenue growth rate	2.3%
Return on equity	3.7%
Net Margin	4.0%
Next Earnings Update	05 Feb 2025

Recent past performance updates

No updates

Recent updates

No updates

Revenue & Expenses Breakdown

How KYORIN Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

OTCPK:KYRN.F Revenue, expenses and earnings (JPY Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
30 Sep 24	119,734	4,820	36,890	8,019
30 Jun 24	120,097	5,531	37,055	8,019
31 Mar 24	119,532	5,322	37,375	8,019
31 Dec 23	119,830	4,260	35,636	10,903
30 Sep 23	119,114	5,238	35,807	10,903
30 Jun 23	116,505	4,216	35,112	10,903
31 Mar 23	113,270	4,723	34,140	10,903
31 Dec 22	108,524	5,826	34,575	8,897
30 Sep 22	105,525	5,053	33,931	8,897
30 Jun 22	105,458	5,577	34,316	8,897
31 Mar 22	105,534	3,932	35,536	8,897
31 Dec 21	105,666	4,109	34,767	9,703
30 Sep 21	104,271	4,133	35,256	9,703
30 Jun 21	102,910	4,059	36,827	9,703
31 Mar 21	102,904	6,130	36,138	9,703
31 Dec 20	106,324	6,279	37,384	10,987
30 Sep 20	109,419	7,433	38,096	10,987
30 Jun 20	108,923	6,478	37,870	10,987
31 Mar 20	109,983	6,149	38,541	10,987
31 Dec 19	110,217	6,131	37,430	10,790
30 Sep 19	111,559	5,486	37,662	10,790
30 Jun 19	114,238	7,072	37,559	10,790
31 Mar 19	113,620	6,869	37,646	10,790
31 Dec 18	109,734	5,567	35,873	14,243
30 Sep 18	110,242	7,551	36,073	14,243
30 Jun 18	109,313	5,258	38,383	14,243
31 Mar 18	110,640	6,574	38,510	14,243
31 Dec 17	111,460	8,701	37,987	13,569
30 Sep 17	111,503	5,861	39,596	13,569
30 Jun 17	114,124	7,118	39,692	13,569
31 Mar 17	115,373	7,305	40,544	13,569
31 Dec 16	116,850	7,531	41,082	13,019
30 Sep 16	121,725	13,356	39,875	13,019
30 Jun 16	120,623	14,462	38,802	13,019
31 Mar 16	119,483	13,639	39,467	13,019
31 Dec 15	118,988	13,324	39,731	13,514
30 Sep 15	114,395	11,536	39,814	13,514
30 Jun 15	113,291	11,140	39,795	13,514
31 Mar 15	113,121	12,064	38,271	13,514
31 Dec 14	111,572	12,324	39,388	11,359
30 Sep 14	111,661	11,123	39,027	11,359
30 Jun 14	111,558	11,710	39,127	11,359
31 Mar 14	111,400	12,025	39,385	11,359
31 Dec 13	111,232	12,432	40,105	11,059

Quality Earnings: KYRN.F has high quality earnings.

Growing Profit Margin: KYRN.F's current net profit margins (4%) are lower than last year (4.4%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: KYRN.F's earnings have declined by 5.4% per year over the past 5 years.

Accelerating Growth: KYRN.F's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: KYRN.F had negative earnings growth (-8%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (54.6%).

Return on Equity

High ROE: KYRN.F's Return on Equity (3.7%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2024/12/23 10:40
End of Day Share Price	2024/10/23 00:00
Earnings	2024/09/30
Annual Earnings	2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

KYORIN Pharmaceutical Co., Ltd. is covered by 8 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Ritsuo Watanabe	BofA Global Research
Hidemaru Yamaguchi	Citigroup Global Markets Japan Inc.
Hidemaru Yamaguchi	Citigroup Inc